Ke Ying Liu
Director/Board Member chez Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Profil
Ke Ying Liu is currently a Director at Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Previously, Liu held the position of Chairman-Supervisory Board at Jiangsu Provincial Agricultural Reclamation & Dev Co., Ltd.
Postes actifs de Ke Ying Liu
| Sociétés | Poste | Début |
|---|---|---|
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is an innovative pharmaceutical group enterprise based in Lianyungang, China. Chia Tai Tianqing has six major product groups, including liver disease, anti-tumor, respiratory, infection, endocrine, and cardiovascular and cerebrovascular. The Chinese company invests heavily in innovative drug research and has high-level R & D platforms such as the national enterprise technology center. Chia Tai Tianqing is preparing for a number of products to enter the international market and actively undertakes corporate social responsibilities. The private company was founded in 1969, and the CEO is Kang Xin Yu. | Director/Board Member | - |
Anciens postes connus de Ke Ying Liu
| Sociétés | Poste | Fin |
|---|---|---|
| JIANGSU PROVINCIAL AGRICULTURAL RECLAMATION AND DEVELOPMENT CO.,LTD. | Chairman | 22/09/2023 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| JIANGSU PROVINCIAL AGRICULTURAL RECLAMATION AND DEVELOPMENT CO.,LTD. | Process Industries |
| Entreprise privées | 1 |
|---|---|
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is an innovative pharmaceutical group enterprise based in Lianyungang, China. Chia Tai Tianqing has six major product groups, including liver disease, anti-tumor, respiratory, infection, endocrine, and cardiovascular and cerebrovascular. The Chinese company invests heavily in innovative drug research and has high-level R & D platforms such as the national enterprise technology center. Chia Tai Tianqing is preparing for a number of products to enter the international market and actively undertakes corporate social responsibilities. The private company was founded in 1969, and the CEO is Kang Xin Yu. | Health Technology |
